# Bioarray Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bioarray-therapeutics

- Industry: Biotechnology
- Headquarters: Farmington, US
- Website: www.bioarray.us
- Total disclosed funding: $5.3M
- Latest round: Series B (Oct 5, 2017)
- Investors on record: 3

## About

Bioarray Therapeutics Inc. develops and provides advanced array-based diagnostic tools aimed at enhancing disease detection and pathogen identification across various sectors.Founded in 2009 in Farmington, US, Bioarray Therapeutics Inc. specializes in biotechnological solutions for diagnostic applications. The company has successfully raised USD 4.00 mn in funding through a Series B round on October 5, 2017, led by GF Securities and Quark Venture, with participation from Connecticut Innovations. Katherine Martin, the founder, has a history of involvement in the biotechnology sector, though details of previous ventures are not specified.Bioarray Therapeutics Inc. specializes in advanced biotechnological solutions, primarily focusing on the development and provision of innovative array-based diagnostics tools. Their core product offerings include high-throughput bioassay platforms that enable the detection and analysis of biological samples for various applications in research, clinical diagnostics, and agricultural biotechnology. These products address critical challenges in health and environmental monitoring, such as early disease detection and pathogen identification, which are vital in both clinical settings and agricultural practices. The end users of these products range from clinical laboratories, research institutions, and healthcare providers to agricultural enterprises looking to enhance crop disease management. Bioarray Therapeutics Inc. markets its solutions across North America, Europe, and select markets in Asia, ensuring a broad reach in the global biotechnology sector.The revenue model of Bioarray Therapeutics Inc. is primarily structured around direct sales of their diagnostic products and services to both businesses and end consumers. Transactions typically occur through B2B partnerships with healthcare institutions, research organizations, and agricultural firms, allowing for tailored solutions that meet specific client needs. Pricing plans may include one-time purchases for individual products or tiered pricing for bulk orders, catering to the scale of the client’s requirements. Additionally, the company may offer service packages that include ongoing support and maintenance for their diagnostic platforms, which further enhances client retention and satisfaction. Overall, Bioarray Therapeutics Inc. generates revenue through a combination of direct product sales and service contracts, ensuring a sustainable financial model within the biotechnology industry.In October 2017, Bioarray Therapeutics Inc. raised USD 4.00 mn in Series B funding to support its ongoing development and market expansion. The funding will be utilized to enhance its product offerings, particularly focusing on upcoming innovative diagnostic tools designed for early disease detection and environmental monitoring. The company plans to expand its market reach, targeting specific regions in Asia and Europe for new partnerships and sales channels by the end of 2023.

## Funding rounds

- Series B, Oct 5, 2017, $4M — Connecticut Innovations, GF Securities, Quark Venture
- Series A, May 1, 2015, $1.3M — Connecticut Innovations

## Investors

- Connecticut Innovations (https://capitalatlas.ai/funds/connecticut-innovations) — Series A, Series B
- GF Securities — Series B
- Quark Venture (https://capitalatlas.ai/funds/quark-venture) — Series B